Strategic Analysis of the European Specialty Pharma Market

This Frost & Sullivan research service titled Strategic Analysis of the European Specialty Pharma Market provides the market overview, market engineering research, competitor analysis and therapeutic area-wise opportunity analysis. This research service includes an examination of how the healthcare delivery models differ from one country to another, the regulatory framework for healthcare companies as well as the regulatory barriers to entry, and the best route to market for both global companies and smaller market participants alike. The following market segments have been covered in this research: cardiovascular diseases, central nervous system disorders, ophthalmology, women's health, and urology.

This analysis is available through our Pharmaceuticals & Biotechnology Growth Partnership Services programme. With continuous access to intelligence and resources from all seven perspectives of the Complex Business Universe, the Growth Partnership Services programme ensures that you and your Growth Team??? are able to maintain a 360 Degree Perspective of the market. This comprehensive, objective information allows your company to mitigate risk, identify new opportunities, and drive effective strategies for growth. For more information on this custom subscription service, please click here.

Market Overview

Innovative Business Models and Focus on Niche Therapeutic Areas Bolster the European Specialty Pharmaceutical Markets

Confronted by a vast array of challenges such as declining R&D productivity and the loss of patent protection of key brands, participants in the pharmaceuticals market are exploring innovative and novel approaches to developing drugs. Given the high degree of unmet needs in specialised therapeutic areas, focussing on developing drugs for niche areas presents several opportunities for specialty pharma companies. "The competitive pressures in the pharmaceutical industry are driving market participants to create new business models," says the analyst of this research. "For instance, companies focused on pure drug delivery have started to invest in R&D to develop indigenous products, while companies dependent on the in-licensing model are attempting to boost internal pipelines."

Lifecycle management technologies, which were once restricted to drug delivery companies, have gradually been adapted by several specialty pharma and generic companies. However, the commoditisation of several drug delivery technologies is adversely affecting specialty pharmaceuticals. "The increasing uptake of generics in most European countries has undermined the attractiveness of life cycle management of legacy products, especially in the case of sophisticated oral drug-delivery technologies," explains the analyst. "Such increased commoditisation is likely to affect the revenues of companies that are specifically focused on reformulation, with the possibility of bigger companies wanting to acquire them as a part of their expansion plans."

Technological innovation and leadership are expected to be a key differentiating factor in the future. The commoditisation of several drug-delivery technologies, particularly in the oral dosage form arena, is driving companies to invest more in R&D. Additionally, applying technological differentiation strategies to compounds that are available in generic forms provides specialty pharmaceutical firms access to the market segments of mainstream indications without having to invest in expensive brand-building and post-market clinical development strategies. "In a changing competitive environment, only those companies that have demonstrated their ability to innovate, create, and market new products are likely to prosper," concludes the analyst.

Market Sectors

Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:

By Application:

• Cardiovascular diseases
• Central nervous system disorders
• Ophthalmology
• Women's health
• Urology